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The Journal of Infectious Diseases
Rapid Protective Effects of Early BCG on Neonatal 
Mortality Among Low Birth Weight Boys: Observations 
From Randomized Trials
Sofie Biering-Sørensen,1,2 Kristoffer Jarlov Jensen,1,2,3 Ivan Monterio,1 Henrik Ravn,2 Peter Aaby,1,2 and Christine Stabell Benn1,2,4
1Projécto de Saúde Bandim, INDEPTH Network, Guinea-Bissau; 2Research Center for Vitamins and Vaccines, Bandim Health Project, Statens Serum Institut, Copenhagen; 
3Section for Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark; and 4Odense Patient data Explorative Network, Institute of Clinical 
Research, University of Southern Denmark/Odense University Hospital Denmark
Background. Three randomized trials (RCTs) in low-weight (<2.5 kg) infants have shown that Bacille Calmette-Guérin (BCG) 
vaccine nonspecifically reduces all-cause mortality in the neonatal period.
Methods. Using data from 3 RCTs of early BCG (n = 6583) we examined potential sex differences in the timing of the mortality 
reduction in the neonatal period, presenting metaestimates of the main outcome mortality rate ratios (MRR) for BCG-vaccinated 
and controls.
Results. Among controls, boys had a particularly high mortality during the first week after randomization: male–female MRR 
2.71 (95% CI, 1.70–4.50). During the first week, BCG had a marked beneficial effect for boys, reducing mortality 3-fold (MRR [BCG/
no BCG] = 0.36 [0.20–0.67]). In weeks 2–4 the effect waned for boys (MRR = 0.91 [0.51–1.69]). In girls, the pattern was opposite 
with a limited effect in the first week (MRR = 0.85 [0.46–1.54]), but a significant reduction in weeks 2–4 (MRR = 0.56 [0.31–1.00]). 
This was consistent in all 3 trials. Verbal autopsies linked early benefit to fewer sepsis-related deaths among BCG-vaccinated boys.
Discussion. The marked reduction in mortality in the days after BCG vaccination in boys emphasizes the importance of pro-
viding BCG soon after birth.
Trial registration numbers: ClinicalTrials.gov (NCT00146302) and ClinicalTrials.gov (NCT00625482).
Keywords: Bacille Calmette-Guérin vaccine; heterologous immunity; nonspecific effects of vaccines; sex differences; neonatal 
mortality. 
Observational studies have suggested that Bacille Calmette-
Guérin (BCG) vaccine is associated with lower all-cause mor-
tality in addition to protecting against tuberculosis [1, 2]. We 
have called this phenomenon the nonspecific effects of BCG.
In many low-income countries, including Guinea-Bissau, 
BCG is postponed for low-birth-weight (<2500  g) neonates 
until they have attained a weight of 2500 g. It was therefore pos-
sible to conduct randomized trials (RCTs) among low-weight 
(LW) infants to test the hypothesis that BCG at birth reduced 
infant mortality by 25%. Between 2002 and 2008, we conducted 
2 RCTs of early BCG showing a nonsignificant reduction of 21% 
in infant mortality, but a significant reduction of 48% in neona-
tal mortality [3]. Because the first 2 trials had infant mortality as 
the primary outcome, we subsequently conducted a third RCT 
(2008–2013) with neonatal mortality as the main outcome. 
A combined analysis of all 3 trials showed significant reductions 
of 38% in neonatal mortality and 16% in infant mortality [4]. 
The 3 trials supported consistently that BCG has strong benefi-
cial effects on mortality in the first month of life.
While analyzing the first 2 RCTs we observed that the benefi-
cial effects of BCG had different timing for boys and girls. Before 
publishing, we awaited the results of the third trial, which has 
now been completed [4]. Here, we present the sex-differential 
time trend in the effect of BCG on neonatal mortality in the 3 
RCTs conducted in LW infants in Guinea-Bissau.
METHODS
Background
The Bandim Health Project (BHP) maintains a health and 
demographic surveillance system in Bissau, the capital of 
Guinea-Bissau. The first LW trial began in November 2002 
(ClinicalTrials.gov, NCT00146302) [3]. All LW children 
from the city of Bissau born at the maternity ward of the 
national hospital, as well as LW children coming for vacci-
nation to the health centers in the study area, were invited 
to participate in the trial. In November 2004, we discovered 
that there were faulty randomization procedures at the main 
hospital and the trial was stopped. The randomization pro-
cedures occurred without error at the health centers (Trial 
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1)  [5]. The trial was reorganized and new randomization 
and control procedures were introduced. Therefore, from 
November 2004 to February 2008, recruitment to a second 
RCT took place at the maternity ward at the national hospi-
tal and at the 3 health centers in the study area (Trial 2) [3]. 
In 2008, a third RCT was initiated to test the hypothesis 
that early BCG reduces neonatal mortality by 45% (Trial 3, 
ClinicalTrials.gov, NCT00625482). Similar to Trials 1 and 2, 
recruitment to Trial 3 took place at the national hospital and 
the 3 health centers in the study area as well as 3 private hos-
pitals. Initially, Trial 3 included only girls; based on growth 
data we initially thought that BCG was particularly benefi-
cial for girls, but when Trial 2 found that early BCG vaccina-
tion also benefitted boys, we applied for ethical permission 
to enroll boys in Trial 3 as well. Hence, from May 2010, Trial 
3 was expanded to include also boys.
Study Design and Randomization
Trials 1, 2, and 3 were identical in design. Hence, the present 
study uses data from all 3 trials. The inclusion and follow-up 
procedures have been described in detail elsewhere [3–5]. 
In brief, LW children were identified at discharge from the 
hospital or at their first health center contact, and they were 
randomly assigned to early BCG (intervention group) or the 
usual delayed BCG (control group). Eligible participants were 
children with a weight less than 2500 g at the time of enrol-
ment. Children, who had major malformations, were overtly 
sick, or who had received the BCG vaccine prior to enrolment 
were excluded from the study. Mothers/guardians of eligible 
children were informed about the study in the local language, 
Creole, and received a written explanation in the official lan-
guage, Portuguese. If they wished to participate, we asked the 
mother or guardian to sign the consent form with a signature 
or fingerprint. The children were randomized (1:1) in blocks 
of 24. To illustrate for the mother/guardian that it was chance 
that decided what intervention the child would receive, the 
mother/guardian was asked to draw a lot from a bag containing 
24 envelopes. In Trials 1 and 2, pairs of twins were randomized 
to the same treatment to eliminate potential confusion of the 
individual twins; in Trial 3, only same-sex twins were random-
ized to the same treatment.
Children in the intervention group received BCG intra-
dermally (0.05  mL BCG Vaccine SSI; Statens Serum Institut, 
Copenhagen, Denmark). Control children were treated accord-
ing to local practice and received BCG vaccine later when they 
attended a health center and had attained a weight of 2500 g or 
at 6 weeks of age, when infants were to receive the first doses 
of diphtheria, pertussis, and tetanus (DTP) and oral poliovi-
rus (OPV) vaccines. All children received a birth dose of OPV 
(OPV0) at inclusion except for 99 children included between 
15 October and 9 December 2007 when OPV was lacking in 
Guinea-Bissau.
From May 2005 to January 2008 (Trial 2), we also studied 
the effect of vitamin A  supplementation (VAS) at birth in a 
2-by-2 factorial design. The children were randomly assigned 
to early BCG or delayed BCG as well as vitamin A supplemen-
tation or placebo. Because there was no interaction in mortality 
between the 2 interventions [3], the effects of BCG and VAS 
were reported separately [6].
Children living outside the BHP study area were driven 
home by a field team. The team drew a map of the house, re-
corded global positioning system (GPS) coordinates, and took 
a photograph of the house and the mother to ensure that the 
team would be able to identify the child at subsequent visits. 
The children were visited at home after 3 days and at 2, 6, and 
12  months of age to assess the status of the child. Children 
from the study area were identified via their unique study 
number and followed both by the routine visits by the BHP 
assistants and at the study specific visits at 3 days and at 2, 6, 
and 12 months of age.
Verbal Autopsy Procedures
Verbal autopsies were conducted to determine probable causes 
of death. During Trial 1 and 2, a medical practitioner visited the 
home 3  months after the child had died. The medical practi-
tioner registered the events leading up to the death of the child, 
and assigned a cause of death based on this information. In Trial 
3, a field assistant trained in performing verbal autopsies visited 
the home 3 months after the child had died. The field assistant 
recorded events leading up to the death of the child. Based on 
this information, the medical practitioner, who had assigned 
the causes of death in Trial 1 and 2, assigned the causes of death 
in Trial 3. The medical practitioner was unaware of the inter-
vention allocation.
Statistical Analysis
Cox proportional hazards models with time since random-
ization as the underlying time variable were used to com-
pare mortality rates between the intervention and the control 
group, providing mortality rate ratios (MRR). Children 
entered the analyses at the day of randomization and exited 
at death or at the end of the neonatal period (28 days of age). 
Children who moved before 28 days of age were censored. 
We used robust 95% confidence intervals (CI) to adjust the 
standard errors for the lifetime dependence between twins. 
Time from randomization to 28 days was divided into inter-
vals, and within these intervals we analyzed the effect of early 
BCG. Because most deaths occurred in the first week after 
randomization, we divided it into 2 intervals of 0–3 days and 
4–7 days after randomization; the remaining time of the neo-
natal period was analyzed in weekly intervals. We allowed 
a different baseline hazard for each of the 3 trials. When 
there were 0 deaths in the intervention group (MRR = 0), 
CIs were obtained by a profile likelihood method, inverting 
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results of the likelihood ratio test into a CI. We evaluated 
the proportional-hazards assumption by log-log plots and 
Schoenfeld residuals. Kaplan-Meier curves with time since 
randomization as the underlying time were drawn to display 
the cumulative mortality between the intervention and con-
trol group for Trials 1–3 combined and for Trials 2 and 3 
separately (Trial 1 had too few deaths for graphic presenta-
tion). All analyses were performed separately for boys and 
girls because the focus of the present study was to determine 
whether the effect of BCG differed by sex.
Ethics
The Guinean Ministry of Health’s Research Coordination 
Committee approved all trials and we received consultative 
approval from the Danish Central Ethical Committee for all 
trials. Children enrolled in the study had access to free con-
sultations and essential drugs at the health centers in the BHP 
study area.
Participant Involvement
No participants were actively involved in setting the research 
question or the outcome measures, nor were they involved in 
the analysis, interpretation, and writing of the results. The par-
ticipants are thanked in the acknowledgments. Our findings 
from the study have been shared with the Ministry of Health in 
Guinea-Bissau, to inform policy.
RESULTS
In Trial 1, 105 children were included and 1 child was excluded 
(Figure 1). In Trial 2, 2343 children were invited to participate 
and 23 were excluded. In Trial 3, 4193 children were invited 
and 34 were excluded. A total of 58 children were enrolled after 
the neonatal period and were not included in the present anal-
ysis. We therefore analyzed 6525 children and among them 189 
deaths occurred during the first 28 days of life. At baseline, the 
randomization groups were comparable in each of the 3 trials 
[3–5]. In the combined population of the 3 trials, the interven-
tion and control groups were comparable when stratified by 
sex (Supplementary Table 1). The median age of inclusion was 
2 days (10–90 percentiles: 2–10 days) in all 3 trials.
For both sexes, the highest mortality rate was seen in the first 
3 days after enrolment (Table 1, Figure 2). The mortality rate 
was much higher for control boys than for control girls partic-
ularly in the first 7 days after enrolment, the male-female MRR 
being 2.71 (95% CI, 1.64–4.50). After the first week, the MRR 
comparing boys and girls was reduced to 1.25 (95% CI, 0.70–
2.22) (data not shown).
The mortality curves for the 2 randomization groups (early 
BCG and control) for all trials combined and individually for 
Trials 2 and 3 are depicted in Figure 3. The effect of BCG was 
consistently different for boys and girls for Trials 2 and 3 individ-
ually and for all 3 trials combined. Trial 1 had too few deaths to 
Trail 1: Invited to
participate N = 105
Trail 2: Invited to
participate N = 2343
Randomised total
N = 6583
Status at 28 days of life
Alive (n = 3177)
Died (n = 73)
Moved (n = 13)
Refused visit (n = 3)
Censored before 28 days (n = 0)
Status at 28 days of life
Alive (n = 3121)
Died (n = 116)
Moved (n = 14)
Refused visit (n = 5)
Censored before 28 days (n = 3)
Trail 3: Invited to
participate N = 4193
Excluded (wrong
weight): N = 1
Randomised N = 104
Included after 28 days
N = 32
Included after 28 days
N = 26
Early BCG N = 3266 Control N = 3259
Randomised N = 2320 Randomised N = 4159
Excluded (wrong weight,
malformation, refusal, wrong
treatment): N = 23
Excluded (malformation,
refusal, BCG before inclusion,
not randomized due to error,
 wrong treatment): N = 34
Figure 1. Children enrolled in 3 trials of early BCG effects on neonatal mortality in Guinea-Bissau 2002–2013. Note: The flow of children in each trial has been described 
in detail elsewhere [3–5]. Abbreviation: BCG, Bacille Calmette-Guérin.
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be presented graphically, although a strong early effect for boys 
was also observed in this trial (Table 2). Hence, the more rapidly 
occurring reduction in mortality after BCG for boys compared 
with girls was present in all 3 trials (Figure 3 and Table 2).
When analyzing all 3 trials combined, during the first 7 days after 
enrolment BCG versus control was associated with a significant 
reduction in mortality (1–3 days: MRR = 0.36 [95% CI, 0.16–0.80] 
and 4–7 days: MRR = 0.37 [95% CI, 0.14–0.94]) for boys (Table 
1). In girls, there was only a very small effect of BCG at 1–3 days 
(MRR = 0.84 [95% CI, 0.41–1.73]) and 4–7 days (MRR = 0.85 [95% 
CI, 0.29–2.53]). This resulted in an interaction between sex and 
BCG in the first 7 days (P = .05 for interaction). In the following 3 
weeks, boys had only a limited response to BCG (MRR = 0.91 [95% 
CI, 0.51–1.69]); however, girls had a significant 44% reduction in 
mortality from day 8 to 28 after birth (MRR: 0.56 [95% CI, 0.31–
1.00]). Hence, the effect of BCG in boys and girls was significantly 
different in the first 1–7 days compared to the subsequent 8–28 days 
(P = .03 for 3-way interaction). We also tested other cut points from 
day 1 to 14 to verify that the 3-way interaction between BCG, sex, 
and time interval was not a chance observation (Supplementary 
Table 2). For all cut points in the first 14 days after enrolment, we 
observed the pattern of a stronger beneficial effect for boys in the 
first time interval and a stronger effect for girls in the second time 
interval. However, the strongest differential effect was seen for cut 
points between 4 and 10 days after enrolment and the most signif-
icant 3-way interaction was seen at 6 days after enrolment (P = .02 
for interaction). When stratifying by trial, the same sex-differential 
time course effect of BCG was evident in all 3 trials (Table 2).
We had verbal autopsy information on cause of death from 
95% (179/189) of the deaths that occurred in the neonatal period 
(Table 3). Sepsis was the cause of 50% of the deaths (90/179), 
other infections accounted for 19% (34/179) and noninfec-
tious causes were 31% (55/179). For both sexes combined, BCG 
reduced sepsis-related mortality by 43% (MRR = 0.57 [95% CI, 
0.36–0.91]) and other infections by 52% (MRR = 0.48 [95% CI, 
0.21–1.08]), whereas the effect was limited for noninfectious 
causes (MRR = 0.89 [95% CI, 0.50–1.58]). Among boys, there 
was a significant reduction in sepsis-related deaths at 1–28 days 
(MRR = 0.51 [95% CI, 0.26–0.95]); however, this occurred most 
strongly in the first week (MRR = 0.37 [95% CI, 0.14–0.88]); 
for girls the reduction in sepsis-related deaths was strongest in 
weeks 2–4 after enrolment (MRR = 0.46 [95% CI, 0.14–1.29]).
DISCUSSION
Using data from 3 RCTs of early BCG, the present analysis found 
a rapidly occurring protective effect on mortality in boys; the 
effect was strongest for boys in the first week after receiving BCG, 
whereas there was little or no effect in the remainder of the neo-
natal period. This pattern differed significantly from that seen in 
girls, who had the strongest beneficial effect in weeks 2–4.
Strength and Weaknesses
The time course of the protective effect of BCG on mortality 
has not been examined previously. All 3 RCTs showed a strong 
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Figure 2. Mortality rates split into time intervals since randomization, presented 
by sex and randomization groups. Abbreviation: BCG, Bacille Calmette-Guérin.
Table 1. Mortality Rate Ratios (MRR) for Different Intervals of Time Since Randomization to Early BCG or Control Group, Stratified by Sex
Boys Girls
Mortality per 100/PY (deaths/PY) MRR for Early BCG 
versus Control  
(95% CI)
Mortality per 100/PY (deaths/ PY) MRR for Early BCG 
versus Control  
(95% CI)Early BCG Group Control Group Early BCG Group Control Group
Divided into small 
intervals
1–3 days 83 (8/9.6) 232 (22/9.5) 0.36 (0.16–0.80) 82 (14/17.1) 100 (17/17.1) 0.84 (0.41–1.73)
4–7 days 47 (6/12.7) 130 (16/12.4) 0.37 (0.14–0.94) 27 (6/22.6) 31 (7/22.5) 0.85 (0.29–2.53)
8–14 days 50 (10/21.5) 38 (8/21.1) 1.23 (0.49–3.11) 33 (13/38.8) 52 (20/38.6) 0.64 (0.32–1.29)
15–21 days 35 (7/20.0) 52 (10/19.4) 0.68 (0.26–1.79) 11 (4/36.2) 28 (10/35.7) 0.39 (0.12–1.26)
22–28 days  36 (4/13.4) 37 (4/13.2) 0.82 (0.19–3.50) 4 (1/24.7) 8 (2/24.4) 0.50 (0.05–5.45)
Divided into larger 
intervals
1–7 days 63 (14/22.2) 174 (38/21.9) 0.36 (0.20–0.67) 51 (20/39.7) 61 (24/39.6) 0.84 (0.46–1.54)
8–28 days 38 (21/55.1) 41 (22/53.8) 0.91 (0.51–1.69) 18 (18/99.7) 32 (32/98.7) 0.56 (0.31–1.00)
Estimates with P < .05 are highlighted in bold.
Abbreviations: BCG, Bacille Calmette-Guérin; PY, person years.
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early beneficial effect of BCG in boys, a pattern different from 
that seen in girls.
The loss to follow-up was very low and only 0.6% of the chil-
dren did not have complete follow-up in the neonatal period. 
Therefore, we do not believe that deaths were underreported in 
any group. The randomization was not blinded to the trial team, 
as the vaccinations were registered on the children’s health cards. 
This was done to ensure that control mothers would return to 
the health centers to get their children vaccinated with BCG 
when they had gained weight. The staff members working on 
the 3 trials were not involved in providing health care for study 
children, and health care providers at the hospital and health 
centers were not aware of the trials. It is therefore unlikely that 
lack of blinding affected subsequent treatment.
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Figure 3. Mortality curves for Trials 1, 2, and 3 combined and separately for Trial 2 and Trial 3. Note: It was not possible to calculate a separate mortality curve stratified 
by sex for Trial 1 due to few deaths within the neonatal period (n = 2 girls, n = 6 boys). Abbreviation: BCG, Bacille Calmette-Guérin.
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Biological Mechanisms
The rapid protective effect of BCG vaccination on all-cause 
mortality in humans was first described in connection with 
the present trials [3–5]. A study in adult mice found that BCG 
administered 24 hour prior to challenge with Klebsiella pneu-
moniae significantly improved survival, and a protective effect 
was also seen when BCG was administered 1 hour after the 
challenge [7]. The rapid onset of these effects suggests that 
innate immune mechanisms are involved. The innate immune 
system can be stimulated nonspecifically, resulting in increased 
protection against unrelated infections, a phenomenon that 
has been called trained innate immunity [8]. Innate training 
effects of BCG has recently been demonstrated in healthy adult 
volunteers, in whom BCG was associated with increased proin-
flammatory in vitro cytokine responses to unrelated pathogens 
2 weeks and 3  months after vaccination. Mechanistic stud-
ies showed that this was due to epigenetic reprogramming of 
monocytes [9]. In severe combined immune deficiency (SCID) 
mice, lacking an adaptive immune system, BCG was associ-
ated with no mortality after challenge with a Candida infection 
which was otherwise lethal in nonvaccinated mice [9]. These 
effects were not analyzed by sex. We have recently shown, in 
an immunological study of a subgroup of the infants enrolled 
in Trial 3, that BCG was associated with increased proinflam-
matory in vitro cytokine responses to innate agonists 4 weeks 
after vaccination [10], consistent with the findings from the 
Table  3. Mortality Rate Ratios (MRR) of Causes of Deaths Stratified by Sex, Presented as the Complete Period or Split into Time Intervals since 
Randomization
Boys Girls
Causes of Deaths
Early BCG Control
MRR (BCG/Control)
Early BCG Control
MRR (BCG/Control)N Deaths/PY N Deaths/PY
1–28 days after randomizationa
Sepsis 16/77.3 31/75.7 0.50 (0.27–0.92) 17/139.5 26/138.4 0.66 (0.36–1.21)
Other infectionsb 7/77.3 14/75.7 0.49 (0.20–1.22) 4/139.5 10/138.4 0.40 (0.12–1.27)
Noninfectionsc 11/77.3 13/75.7 0.82 (0.37–1.81) 15/139.5 15/138.4 1.00 (0.48–2.08)
Time intervals since randomizationa
1–7 days after randomization
Sepsis 8/22.2 21/21.9 0.37 (0.17–0.84) 11/17.1 13/17.1 0.86 (0.38–1.91)
Other infectionsb 2/22.2 8/21.9 0.25 (0.05–1.16) 2/17.1 5/17.1 0.40 (0.08–2.06)
Noninfectionsc 3/22.2 7/21.9 0.42 (0.11–1.64) 6/17.1 4/17.1 1.51 (0.43–5.37)
8–28 days after randomization
Sepsis 8/55.1 10/53.8 0.76 (0.29–1.96) 6/99.7 13/98.7 0.46 (0.17–1.20)
Other infectionsb 5/55.1 6/53.8 0.82 (0.25–2.68) 2/99.7 5/98.7 0.39 (0.08–2.03)
Noninfectionsc 8/55.1 6/53.8 1.27 (0.44–3.62) 9/99.7 11/98.7 0.81 (0.32–2.02)
Estimates with P < .05 are highlighted in bold.
Abbreviations: BCG, Bacille Calmette-Guérin; PY, person years.
a10 verbal autopsies were not conducted due to the respective families having moved outside the catchment area before the verbal autopsy visit.
bThe category ‘Other infections’ consists of deaths due to fever, respiratory infections, gastrointestinal infections, infections in the umbilical cord, malaria, or HIV.
cThe category ‘Noninfections’ consists of deaths due to prematurity, anemia, congenital problems, kernicterus, sudden infant death syndrome, gastrointestinal hemorrhage, convulsions, 
or bleeding.
Table 2. Mortality Rate Ratios (MRR) in Time Intervals (0–7 days and 8–28 days) Since Randomization, Stratified by Sex and Trial
Boys Girls
Mortality per 100/PY (deaths/PY)
MRR for Early BCG versus 
CONTROL (95% CI)
Mortality per 100/PY (deaths/PY)
MRR for Early BCG versus 
CONTROL (95% CI)Early BCG Group Control Group Early BCG Group Control Group
Trial 1
1–7 days 0 (0/0.4) 1130 (4/0.4) 0 (0–0.55) 225 (1/0.4) 174 (1/0.6) 1.29 (0.08–20.28)
8–28 days 93 (1/10.7) 142 (1/7.1) 0.36 (0.02–7.00) 0 (0/9.6) 0 (0/12.3) …
Trial 2
1–7 days 86 (8/9.3) 218 (20/9.2) 0.40 (0.17–0.90) 40 (5/12.6) 56 (7/12.4) 0.70 (0.22–2.22)
8–28 days 35 (8/21.6) 37 (7/21.6) 1.14 (0.38–3.91) 20 (6/30.2) 48 (14/29.5) 0.42 (0.16–1.09)
Trial 3
1–7 days 48 (6/12.5) 113 (14/12.3) 0.42 (0.16–1.10) 53 (14/26.6) 60 (16/26.6) 0.84 (0.41–1.73)
8–28 days 41 (12/29.2) 49 (14/28.4) 0.83 (0.39–1.80) 19 (12/62.9) 28 (18/62.4) 0.66 (0.31–1.40)
Estimates with P < .05 are highlighted in bold.
Abbreviations: BCG, Bacille Calmette-Guérin; PY, person years.
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above mechanistic study in adults. Analyzed by sex, the effect 
estimates were larger in girls than in boys for most cytokine 
responses. The stronger immunological effect in girls 4 weeks 
after early BCG is consistent with the findings from the present 
study that 2–4 weeks after BCG vaccination there is a greater 
beneficial effect in females than males.
In the first week after vaccination, BCG decreased the high 
mortality in boys to a level comparable to that of girls. The 
sex-differential and time-dependent effects were particularly 
evident for sepsis-related deaths: BCG decreased sepsis-related 
mortality in boys within the first week after vaccination, with 
no immediate effect in girls, whereas a protective effect against 
sepsis-related mortality in girls was seen after the first week. It 
is well known that newborn boys experience infection-related 
disease and death more frequently than girls [11, 12]. The dis-
similarity may arise from inherent differences in the immune 
function between boys and girls. However, very few studies 
have compared immune function in newborn boys and girls. 
High levels of interleukin-1 (IL-1) receptor antagonist in um-
bilical cord blood from preterm infants were associated with 
adverse outcome in girls but not in boys [13]. After uncompli-
cated pregnancies, cord blood responses to lipopolysaccharide 
stimulation were higher in boys than in girls for IL-1β and IL-6, 
but not tumor necrosis factor-alpha (TNF-α) [14]. The propor-
tion of CD4 T cells in cord blood is higher and the CD4 and 
CD8 T cells express more Fas in girls compared with boys [15], 
indicative of lower apoptotic potential in boys. Although such 
sex-differences in early life immune status have been reported, 
we do not know whether they are related to the sex-differential 
timing of the beneficial effect of BCG.
Implications
Even though the World Health Organization (WHO) recom-
mends BCG at birth to all infants, BCG is often administrated 
much later. Less than 50% receive BCG during the neonatal 
period in Africa [16]. There is no focus on delivering BCG very 
early and there is an inherent flaw in the health infrastructure to 
provide BCG early; for example, many maternity wards do not 
provide BCG before discharge and though WHO recommend 
home visits to newborn children these visits do not include 
vaccinations. Furthermore, there has been a counterproduc-
tive emphasis on reducing wastage of vaccine doses; for BCG, 
this implies that a 20-dose vial is not opened for just 1 child 
and BCG is often given only on specific days to assure that at 
least 10–12 children can be vaccinated [17]. Furthermore, some 
countries do not to give BCG at birth to LW infants. If BCG 
can substantially reduce neonatal mortality, it is important that 
WHO strongly encourage countries to follow their recommen-
dations and provide BCG to all children immediately after birth, 
including LW children. Early administration of BCG should be 
part of the delivery services because that is where the first con-
tact occurs for many children in low-income countries. Because 
boys have much higher mortality than girls in the first week of 
life, it is particularly important that boys receive BCG at birth. 
Receiving a BCG vaccine at birth might reduce the early mor-
tality among boys to the same level as that of girls. Given the 
efficacy of BCG in reducing neonatal mortality it would be cost 
effective to open a vial of BCG even if only 1 child was present.
WHO and other policy makers should take this rapidly 
occurring effect of BCG into account when designing vacci-
nation schedules. For example, if a new tuberculosis vaccine 
is introduced to replace BCG, the new vaccine should be eval-
uated not only for specific protection against tuberculosis but 
also for its nonspecific effect on neonatal mortality. The best 
option might well be to introduce a future tuberculosis vaccine 
for its effect against tuberculosis and maintain BCG at birth as 
an early “immune training” vaccine.
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